In a new study published in Nature Reviews Drug Discovery, Dr. Ajay Gautam at AstraZeneca has proposed a framework for innovation bioclusters across the emerging markets. By analyzing 8 Chinese bioclusters according to their academic and entrepreneurial activity, Dr. Gautam has classified bioclusters as emerging Innovation Leaders, Untapped Talent, Niche Hubs and Aspiring clusters. He has further proposed investment policies for each of such clusters and in a recent blog discussed how AstraZeneca is utilizing this framework for its science strategies in these emerging markets. Bioclusters across China, Korea, Singapore, Brazil, Turkey, Mexico, Russia, India and Israel among others are discussed along with examples of investment strategies as well as AstraZeneca scientific partnerships in these markets.
Ajay spoke at Biopharma Mexico about how Mexico can attract more pharma investment in the country.